fbpx

BACK TO WORK SCHOOL CHURCH SPORTS LIFE

Avrok Laboratories offers surveillance screening for COVID-19 testing.  Test your entire organization at a fraction of the price with pool testing and protect your employees, their family and your business.  Receive results in 24-36 hours and allow your organization to get back to what you do best.  Be part of the BACK TO movement and get your life back!

GET TESTED

NEXT GEN SEQUENCING

Accurate Testing

Next Gen Sequencing (NGS) is measurably more accurate than PCR Covid-19 testing.

Pool Testing

Testing up to 5 people in each pool is cost effective and recommended by the CDC.

Quick Turnaround

Find out results with 24-36 hours of sample pickup. Surveillance testing can get you back to life.

Secure Results

Trusted and secure results are as important to our team as it is to yours.

BY THE NUMBERS

NGS (Next Gen Sequencing) is 99% accurate and up to 74% more cost effective than other COVID-19 testing methods.  The main testing alternative is PCR tests, which have shown to be less accurate than NGS testing.

1 %
ACCURATE
1 %
SAVINGS
Pool testing, which involves collecting groups of samples and testing them at once, could improve our situation significantly.

- Dr. Anthony Fauci

HOW IT WORKS

  • Pick the pooling surveillance program that fits your organization's needs. You can pool up to 5 people per test, saving your business up to 74% off the cost of conventional testing methods.
  • Collect pooled samples from your employees at the frequency you need to keep your staff, colleagues or team safe.
  • Receive a report with a recommendation based on the test results in order to keep everyone working safely.
GET TESTED

ABOUT US

Avrok Laboratories was founded by experts in genetic testing and COVID-19 testing.  Our founders have over 60+ years of experience in infectious diseases.

Donald D. Johnson, Jr., PhD has extensive experience in synthetic chemistry, light/x-ray/electron microscopy, genetics, and molecular biology. He developed his genetics and molecular biology experience at the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI) where he developed PNA-DNA probes for identifying specific species of bacteria harvested from the skin (Human Microbiome Project). He also worked at the National Institute for Biomedical Imaging and Bioengineering (NIBIB) where he developed fluorescent proteins for super resolution microscopy techniques. Dr. Johnson obtained his MS and PhD in Chemistry at the University of California, San Diego.
Don Johnson, Phd.R&D DIRECTOR
Don Johnson, Phd.
Mr. Martin is an entrepreneur with a background in Finance and Business Administration. He has worked in the medical field, where he started, managed and grew the largest private practice in the world. He managed companies with annual revenues of over $30M, and more recently helped KorvaLabs reach $70M in revenue in 7 weeks. He is fluent in 3 languages, which allows him to foster international work relationships.
Jonathan MartinPRESIDENT
Jonathan Martin
Paul Scott is an analytical chemist and the former Director of Clients at the UCLA Olympic Laboratory. Prior to joining the UCLA laboratory, Mr. Scott was a practicing patent attorney at the New York offices of Sidley, Austin, Brown and Wood where his practice was primarily in the biochemical and pharmaceutical industries. Mr. Scott has 20+ years of experience in the use of mass spectrometry directed at the detection of analytes in human fluids and other matrices.
Paul ScottCEO
Paul Scott
Dr. Timothy Triche is the Co-Director for the Children’s Hospital Los Angeles (CHLA) Center for Personalized Medicine. He previously served as Chief of the CHLA Department of Pathology and Laboratory Medicine for over 20 years. Prior to joining CHLA, Dr. Triche was Head of Molecular Diagnostics in the Laboratory of Pathology at the National Cancer Institute. At CHLA, he directs a cancer genomics, biology, and nanotechnology laboratory research program. He has developed numerous biomarker profiles for cancer diagnosis, prognosis and treatment as part of the NCI’s Director’s Challenge, SPECS and TARGET initiatives. His focus is on functional characterization of non-coding RNAs in cancer and development.
Dr. Timothy TricheLABORATORY DIRECTOR
Dr. Timothy Triche
Saboor Hekmaty, M.S., has spent a considerable time building on his expertise in molecular and cellular biology while extending his focus in next-generation sequencing. Having attributed the bulk of his expertise while working at the Icahn School of Medicine at Mount Sinai, he has extensive experience in working and managing a fast-paced high throughput laboratory. Saboor Hekmaty obtained his Masters in Molecular and Cellular Biology at Long Island University, New York.
Saboor Hekmaty, M.S.LABORATORY OPERATIONS DIRECTOR
Saboor Hekmaty, M.S.
Previous
Next

SIGN UP FOR TESTING

Get back to life by activating Avrok Laboratories NGS proprietary COVID-19 surveillance screening allowing your organization to get back to activities in safety.  Contact us and find out what testing plan is right for you and your organization.

FAQ

Most frequent questions and answers

Next Gen Sequencing (NGS) testing.

Results are expected to have a 24-36 turnaround time from the time the samples arrive at the laboratory.

Frequency is your friend on mitigating risk.  The shorter the interval between tests, the better for your organization.

The oral collection is an observed self-collection test that comes with clear and easy instructions for the user.

No.  We use an oral swab.  It is non-invasive and not painful.

All tests will be performed in our laboratory in Azusa, California.

We currently have the capacity to process around 50,000 samples per day.

You can contact us at sales@avroksci.com to partner with an advisor who will help you pick the best program for your organization.

Yes. The CDC, FDA and Dr. Fauci all have looked at Pool Testing as a solution for Covid-19 surveillance testing. 

CDC Pooling Procedures

FDA Pooling Guidance

Washington Post – Fauci New Testing Strategy